The landscape of oncology is undergoing a fundamental shift as the medical community moves away from a one-size-fits-all approach toward precision medicine, where treatments are tailored to the unique genetic and molecular profile of a patient’s tumor. However, the efficacy of these advanced therapies remains tethered to the quality and depth of diagnostic data available to clinicians. Addressing this critical information gap, Waiv, a Paris-based startup, has officially spun out from the artificial intelligence drug discovery unicorn Owkin to operate as an independent entity. This strategic transition is bolstered by a $33 million Series A funding round intended to accelerate the commercialization of its AI-enabled precision testing platform and expand its footprint in the global healthcare market.
The spinout represents a significant milestone for the organization, which previously operated as a specialized diagnostics business unit under the name OwkinDx. By establishing itself as an independent company, Waiv aims to streamline its operations and focus exclusively on developing AI tools that analyze multimodal oncology data to predict disease indicators and patient outcomes. The new capital infusion was led by OTB Ventures and Alpha Intelligence Capital, with participation from a consortium of investors including Serene Data Ventures, Karista, and SistaFund.
The Evolution of Precision Oncology and the Diagnostic Gap
For decades, cancer diagnosis relied heavily on traditional pathology, where clinicians examined tissue samples under a microscope to identify cellular abnormalities. While this method remains a cornerstone of oncology, it often fails to capture the intricate molecular drivers that determine how a specific tumor will respond to modern targeted therapies or immunotherapies. As the pharmaceutical industry introduces a growing number of precision medicines—such as PARP inhibitors for BRCA-mutated cancers or PD-1/PD-L1 inhibitors for various solid tumors—the need for "companion diagnostics" has become paramount.
Waiv enters this market by leveraging the power of "multimodal data," primarily focusing on digital pathology. Digital pathology involves the high-resolution scanning of traditional glass slides into digital images. While these images are vast and complex, often containing gigabytes of data per slide, human pathologists can only interpret a fraction of the information present. Waiv’s AI algorithms are trained to detect "hidden" biological signals within these images—features that are invisible to the human eye but correlate strongly with genetic mutations, protein expression, and clinical prognosis.
According to Meriem Sefta, CEO and co-founder of Waiv, the startup’s technology provides a more detailed picture of a patient’s tumor than traditional methods. By integrating these AI tools directly into existing digital pathology workflows, Waiv allows hospitals and laboratories to perform sophisticated molecular assessments without the need for the expensive, time-consuming, and tissue-intensive processes associated with traditional Next-Generation Sequencing (NGS).
A Strategic Spinout: From OwkinDx to Waiv
The decision to spin out Waiv from its parent company, Owkin, follows several years of internal development and commercial validation. Owkin, known for its federated learning approach to medical research, has established itself as a leader in AI-driven drug discovery, securing massive partnerships with industry giants like Sanofi and Bristol Myers Squibb. While Owkin focuses on the "R" (Research) of R&D, Waiv is designed to bridge the gap between research and clinical application.
During its tenure as OwkinDx, the team successfully commercialized AI tests used to identify patients eligible for specific treatments in both real-world clinical settings and pharmaceutical research. The unit built a robust portfolio of collaborators, including AstraZeneca and Merck, demonstrating the demand for AI diagnostics in streamlining clinical trials and optimizing drug deployment.
The independence of Waiv allows the startup to craft its own "equity story," as Sefta described it. By securing its own investment, Waiv can move with greater agility to meet the specific regulatory and commercial demands of the diagnostics market, which differs significantly from the drug discovery model. This separation ensures that while Owkin continues to innovate in the realm of identifying new drug targets, Waiv can focus on the "last mile" of precision medicine: ensuring the right patient receives the right drug at the right time.
Chronology of Development and Market Context
The emergence of Waiv is part of a broader timeline of innovation in the "TechBio" sector. The journey began with the founding of Owkin in 2016 by Thomas Clozel and Gilles Wainrib, who sought to apply machine learning to vast sets of clinical data while maintaining data privacy through federated learning.
By 2021, Owkin had achieved unicorn status following a $180 million investment from Sanofi. It was during this period of rapid growth that the potential for a dedicated diagnostics arm became clear. OwkinDx was formed to translate the findings from research into tools that could be used at the point of care. Over the next three years, the unit refined its algorithms, focusing on high-incidence cancers where treatment selection is most complex, such as breast, lung, and colorectal cancers.
The timing of Waiv’s independent launch coincides with a surge in interest in AI diagnostics. The global AI in healthcare market is projected to grow from roughly $20 billion in 2023 to over $180 billion by 2030, with diagnostics representing one of the fastest-growing segments. Waiv enters a competitive arena alongside established players like Roche’s Foundation Medicine, Tempus AI, and Caris Life Sciences. However, Waiv’s specific focus on digital pathology images as a primary data source offers a unique value proposition, as it utilizes existing clinical infrastructure (the biopsy slide) rather than requiring additional, invasive samples for genetic testing.
Financial Foundations and Global Ambitions
The $33 million Series A round is a testament to investor confidence in the scalability of Waiv’s business model. Unlike many biotech ventures that require decades to see a return, Waiv operates on a "per-test" basis. This software-as-a-service (SaaS) style model allows for predictable revenue streams as more hospitals adopt the platform.
The lead investors, OTB Ventures and Alpha Intelligence Capital, have emphasized that Waiv’s ability to integrate into "routine diagnostic processes" is a key differentiator. Many advanced diagnostics fail to achieve widespread adoption because they require hospitals to change their entire operating procedure. Waiv’s technology, by contrast, sits on top of the digital pathology systems already being installed in modern medical centers.
The new capital will be allocated toward three primary pillars:
- Clinical Validation: Conducting further large-scale studies to meet the rigorous requirements of regulatory bodies such as the FDA in the United States and the EMA in Europe.
- Commercial Expansion: Building out sales and support teams in North America and Asia to complement their existing European presence.
- Product Diversification: Expanding the AI’s capabilities to include a wider range of cancer types and therapeutic classes beyond their current portfolio.
Industry Implications and the Future of the "Diagnostic Odyssey"
The broader implications of Waiv’s technology extend to the patient experience. Many cancer patients currently endure a "diagnostic odyssey," waiting weeks for complex genetic tests to return before a treatment plan can be finalized. In some cases, the tissue sample collected during a biopsy is insufficient for NGS, leaving clinicians to make treatment decisions based on incomplete information.
AI-enabled precision testing can significantly reduce these wait times. Because Waiv analyzes images that are already generated during the standard diagnostic process, results can potentially be delivered in hours or days rather than weeks. Furthermore, the technology can serve as a screening tool to identify which patients are most likely to benefit from more expensive and invasive downstream testing, thereby optimizing healthcare resources.
From a pharmaceutical perspective, Waiv’s technology addresses the high failure rates of clinical trials. By using AI to identify the "ideal" patient population for a drug during the development phase, pharmaceutical companies can increase the likelihood of trial success and accelerate the path to regulatory approval. This is likely why companies such as AstraZeneca and Merck have already engaged with Waiv’s technology in a research capacity.
Conclusion: A New Era of Data-Driven Care
The spinout of Waiv marks a pivotal moment in the convergence of artificial intelligence and oncology. As an independent entity, Waiv is positioned to challenge the status quo of cancer diagnostics, turning static images into dynamic roadmaps for treatment. While the road to global adoption is fraught with regulatory hurdles and the need for continuous clinical proof, the backing of major venture capital firms and a foundation of successful pharmaceutical partnerships provides Waiv with a formidable starting position.
As precision medicine continues to advance, the bottleneck will no longer be the availability of targeted drugs, but the ability to identify the patients who need them. Waiv’s mission to provide "AI-enabled precision testing" suggests that the next frontier of the war on cancer will be fought not just in the lab, but in the digital pixels of a pathology slide. The $33 million investment is more than just a financial boost; it is a signal that the era of AI-integrated clinical care has moved from theory to commercial reality.
